F. Ivy Carroll

Expertise

Medicinal Chemistry
Biochemical Addiction
Drug Abuse Research

Biography

F. Ivy Carroll, PhD, Distinguished Fellow in medicinal chemistry, appointed August 2002, joined RTI in 1960. He served as director of the Center for Organic and Medicinal Chemistry (1975-2007) and research vice president of the Chemistry and Life Sciences Group (1996-2001). Dr. Carroll has made major scientific contributions in drug discovery and development and other research areas. Among his most recognized scientific contributions is the development of a diagnostic agent for Parkinson's disease and compounds as potential treatments for cocaine and nicotine addictions and other central nervous system disorders. He has published 407 peer-reviewed publications, 33 book chapters, 37 patents, and 21 patent applications. Dr. Carroll has received numerous awards for his research accomplishments, such as the 2006 Nathan B. Eddy Award from the College on Problems of Drug Dependence and the 2006 Research Achievement Award in Drug Design and Discovery from the American Association of Pharmaceutical Scientists. In 2007, he was inducted into the American Chemical Society Medicinal Chemistry Hall of Fame.

Education

PhD, Chemistry, University of North Carolina at Chapel Hill; BS, Chemistry, Auburn University.

Selected Publications

Cai, T.B., Zou, Z., Thomas, J.B., Brieaddy, L., Navarro, H.A., & Carroll, F.I. (Mar 2008). Synthesis and in vitro opioid receptor functional antagonism of analogues of the selective kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl ]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). Journal of Medicinal Chemistry, 51 (6):1849-1860.

Knoll, A.T., Meloni, E.G., Thomas, J.B., Carroll, F.I., & Carlezon, W.A. (2007). Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. Journal of Pharmacology and Experimental Therapeutics, 323 (3):838-845.

Howell, L.L., Carroll, F.I., Votaw, J.R., Goodman, M.M., & Kimmel, H.L. (2007). Effects of combined dopamine and serotonin transporter inhibitors on cocaine self-administration in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics, 320 (2):757-765.

Carroll, F.I., Fox, B.S., Kuhar, M.J., Howard, J.L., Pollard, G.T., & Schenk, S. (2006). Effects of dopamine transporter selective 3-phenyltropane analogs on locomotor activity, drug discrimination, and cocaine self-administration after oral administration. European Journal of Pharmacology, 553 (1-3):149-156.

Thomas, J.B., Zhang, L., Navarro, H.A., & Carroll, F.I. (Sep 2006). Highly potent and selective phenylmorphan-based inverse agonists of the opioid delta receptor. Journal of Medicinal Chemistry, 49 (18):5597-5609.

Carroll, F.I., Melvin, M.S., Nuckols, M.C., Mascarella, S.W., Navarro, H.A., & Thomas, J.B. (Mar 2006). N-substituted 4beta-methyl-5-(3-hydroxyphenyl)-7alpha-amidomorphans are potent, selective kappa opioid receptor antagonists. Journal of Medicinal Chemistry, 49 (5):1781-1791.

Carroll, F.I., Howard, J.L., Howell, L.L., Fox, B.S., & Kuhar, M.J. (2006). Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse. AAPS Journal, 8 (1):E196-E203.

Runyon, S.P., & Carroll, F.I. (2006). Dopamine transporter ligands: Recent developments and therapeutic potential. Current Topics in Medicinal Chemistry , 6 (17):1825-1843.

Carroll, F.I., Chaudhari, S., Thomas, J.B., Mascarella, S.W., Gigstad, K.M., Deschamps, J., & Navarro, H.A. (2005). N-substituted cis-4a-(3-hydroxyphenyl)-8a-methyloctahydroisoquinolines are opioid receptor pure antagonists. Journal of Medicinal Chemistry, 48 (26):8182-8193.

Thomas, J.B., Atkinson, R.N., Vinson, N.A., Catanzaro, J.L., Perretta, C.L., Fix, S.E., Mascarella, S.W., Rothman, R.B., Xu, H., Dersch, C.M., Cantrell, B.E., Zimmerman, D.M., & Carroll, F.I. (2003). Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist. Journal of Medicinal Chemistry, 46 (14):3127-3137.

View all publications by F. Ivy Carroll…